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Abstract 
Objective:  Granular leukocyte-derived myeloperoxidase (MPO) promotes 
oxidation of lipoproteins, while paraoxonase 1 (PON1) has antioxidant properties for 
high-density lipoprotein (HDL).  We evaluated their effects on coronary risk 
stratification and function of lipoproteins. 
Methods and Results:  A total 158 patients who had previously undergone 
percutaneous coronary intervention and who had been hospitalized for coronary 
re-angiography were enrolled.  Coronary lesions (restenosis or de novo lesion) were 
observed in 84 patients but not associated with conventional lipid profile.  In 
contrast, serum MPO levels and PON1 activities were significantly associated with 
the prevalence of coronary lesions.  The high MPO/PON1 ratio, when cutoff values 
were set at 1.59, was independently correlated with restenosis (odds ratio 6.4, 95% 
CI 2.2-19.3, P=0.001) and de novo lesions (odds ratio 3.5, 95% CI 1.3-9.4, P=0.014).  
We isolated HDL from patients with high or low MPO/PON1 ratio, and compared 
anti-inflammatory properties of HDL.  Human umbilical vein endothelial cells were 
stimulated with inflammatory cytokine, and the expression of vascular cell adhesion 
molecule-1 (VCAM-1) was evaluated.  HDL isolated from patients with low serum 
MPO/PON1 ratio inhibited VCAM-1 expression significantly greater than that with 
high MPO/PON1 ratio.  We also demonstrated that the cholesterol efflux capacity 
of apolipoprotein B-depleted serum from patients with high MPO/PON1 ratio was 
significantly decreased than that with low MPO/PON1 ratio.  
Conclusions:  MPO/PON1 ratio could be a useful marker for secondary prevention 
of coronary artery disease through modulation of HDL function. 
 
Keywords: Myeloperoxidase, Paraoxonese-1, high-density lipoprotein, 
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Introduction 
Although high plasma level of low-density lipoprotein cholesterol (LDL-C) is an 
established risk factor for coronary artery diseases (CAD), the adequate 
LDL-lowering therapy with statins has been shown to reduce the prevalence of CAD 
by 30-40% at most [1, 2].  LDL displays several phenotypes such as oxidized LDL 
and small dense LDL, which accelerate atherosclerosis much greater than native 
LDL, therefore the modulation of LDL size and subclasses may be a next therapeutic 
target for the residual cardiovascular risk[3].  On the other hand, high-density 
lipoprotein cholesterol (HDL-C) is a negative risk factor for CAD[4].  HDL exhibits 
a variety of anti-atherogenic functions including anti-inflammatory and 
anti-oxidative as well as promoting reverse cholesterol transport[5].  However, it 
has been reported that HDL may lose its anti-atherogenic properties and become 
pro-atherogenic (dysfunctional) under conditions such as inflammation, diabetes, and 
oxidative stress[5].
 
 These lines of evidence suggest that the function of lipoproteins 
may significantly modulate and predict the progression of CAD in addition to the 
quantity of lipoproteins. 
Myeloperoxidase (MPO) is a heme peroxidase, which is produced from granular 
leukocytes.  Besides its antibacterial effects, MPO causes oxidative- or 
chemical-modification against circulating lipoproteins[6].  In addition, MPO 
generates reactive oxygen and nitrogen species which facilitate lipid peroxidation, 
protein nitration, and protein carbamylation[6].  LDL which undergoes these 
modifications promotes foam cell formation.  On the other hand, the modified HDL 
loses its cholesterol efflux activity and anti-inflammatory properties[7].  Through 
these functional changes, MPO may promote the progression of atherosclerosis.   
Paraoxonase 1 (PON1) is one of the major HDL-associated proteins.  PON1 is 
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strongly lipophilic and co-exists with apolipoprotein (apo)A-I and apo-J in HDL 
particles.  PON1 hydrolyzes organophosphates and its activity is stabilized in the 
presence of the apolipoprotein[8].  PON1 inhibits oxidation of LDL, and reduce 
oxidative stress in blood vessels[8].  In fact, previous studies have shown that the 
activities of PON1 are negatively associated with the prevalence of cardiovascular 
events[9].  Given the function of lipoproteins is impaired by MPO and improved by 
PON1, the plasma level or activity of MPO and PON1 is a marker and modulator of 
not only lipoprotein functions but also initiation and progression of CAD.  However, 
it has not been fully elucidated whether these molecules, alone or in combination, 
predict the prevalence of CAD.  In the present study, therefore, we evaluated serum 
MPO level and PON1 activity in patients with chronic CAD, and validated a 
hypothesis that the MPO/PON1 ratio could be a useful marker for secondary 
prevention of CAD through modulation of HDL functions. 
 
Materials and methods 
Study subjects 
From April 2008 to March 2010, we enrolled 158 consecutive patients who had 
previously undergone successful percutaneous coronary intervention (PCI) with 
stenting one or more times and who had been admitted to Kobe University Hospital 
for the purpose of coronary angiography (CAG) because of 6-month follow-up or 
stable angina or inducible ischemia (CAD group).  On the other hand, 174 patients 
without past history of CAD were enrolled as a non-CAD group in the same period.  
In addition, the CAD group was classified according to the following definition: 
patients who showed restenosis in the original stented segment (in-stent restenosis; 
ISR group); patients with occurrence of other non-target coronary atherosclerotic 
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lesions (de novo lesion group); and patients with neither ISR nor de novo lesion (no 
lesion group).  ISR and de novo lesions were defined as displaying luminal stenosis 
≥ 75% and demonstrating ischemia in the perfusion area of narrowed coronary by 
stress myocardial scintigram.  Weight and height were measured and body mass 
index (BMI) was obtained by dividing a patient’s weight by their height squared.  
Patients who had acute coronary syndrome, renal failure (creatinine >3.0mg/dL), and 
a history of cancer in the previous 5 years were excluded.  Patients whose serum 
C-reactive protein (CRP) was more than 1.0 mg/dL were also not assigned to exclude 
inflammatory diseases (e.g., infections, malignancies, autoimmune diseases), since 
MPO is produced from granular leukocytes, and serum MPO levels might be 
influenced by inflammatory conditions.   All patients gave written informed 
consent, and the clinical study was approved by the Institutional Review Board of 
Kobe University Graduate School of Medicine. The investigation conforms to the 
principles outlined in the Declaration of Helsinki. 
 
Blood chemistry 
Serum was obtained after overnight fast.  LDL-C, HDL-C, apoA-I, apoA-II, apoB, 
apoC-II, apoC-III, apoE, glucose, hemoglobin (Hb)A1c, high sensitivity C-reactive 
protein (hsCRP), and triglyceride (TG) were measured using standard methods at 
Kobe University Hospital.  PON1 paraoxonase activity was measured using 
paraoxon as the substrate by SRL
 
(Kobe, Japan).  The rate of generation of 
p-nitrophenol was determined spectrophotometrically.  Residual serum was stored 
at -80 °C for assays of MPO and PON1 arylesterase activity.  Arylesterase activity 
toward phenyl acetate (Wako Chemicals, Richmond, VA, USA) was measured 
spectrophotometrically at 270 nm in an automated Shimadzu UV-1600, UV-visible 
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Spectrophotometer (Shimadzu, Kyoto, Japan).  Serum was preincubated with 10 
μM eserine (Sigma, St. Louis, MO, USA) for 10 min at room temperature for the 
inhibition of butyrylcholinesterase activity.  The rate of hydrolysis of phenyl acetate 
was determined by adding 10 mM Tris-HCl buffer (pH 8.0) containing 1 mM CaCl2 
and 1 mM phenyl acetate, spectrophotometrically at 270 nm[10].  Serum MPO 
levels were measured by human MPO ELISA kit (Hycult Biotechnology, Uden, 
Netherland) as per manufacturer’s protocol.  
  
Inhibition of tumor necrosis factor-α induced vascular cell adhesion molecule-1 
expression by HDL 
HDL fraction was obtained from the serum with MPO/PON1 ratio < 1 or > 3 by 
ultracentrifugation as described elsewhere[11].  Human umbilical vein endothelial 
cells (HUVEC) were purchased from the American Type Culture Collection 
(Manassas, VA, USA). Subconfluent HUVECs were seeded in a 24 well-plate at 1.2 
x 10
5
 cells/ well.  After 16 hours, the media was replaced with new one containing 
human HDL (100 μg protein/well) which was purified from serum with MPO/PON1 
ratio< 1 or > 3, or bovine serum albumin (control, 100 μg protein/well).  HUVECs 
were incubated for 16 hours, then stimulated with or without tumor necrosis factor 
(TNF)-α (10 ng/ml) for 6 hours.  Experiments were terminated by aspiration of the 
medium and washing cells twice with 500μl of cold phosphate buffered saline.  
Total RNA was extracted using Trizol reagent (Invitrogen, Carlsbad, CA, USA) 
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followed by cDNA preparation using reverse transcript agent, then quantitative 
real-time polymerase chain reaction (PCR) was performed.  PCR primers for human 
vascular cell adhesion molecule-1 (VCAM-1) and glyceraldehyde 3-phosphate 
dehydrogenase were purchased from Takara-Bio Perfect Real Time Support System 
(Takara, Shiga, Japan).   
 
Cholesterol efflux assays 
To quantify HDL efflux capacity, apolipoprotein B-depleted serum was prepared 
from patients with MPO/PON1 ratio>3 or <1 as previously reported[12].  THP-1 
human monocyte cells were seeded into 12 well plates at density of 3 x 10
6
 cells per 
well.  Cells were differentiated into macrophages with phorbol 12-myristate 
13-acetate (Sigma, final concentration 100ng/ml) for 60h.  Cellular cholesterol was 
labeled with 1µCi of [
3
H]-cholesterol for 12h.  Then cells were washed with PBS 
and incubated for 18h with medium containing 0.2% BSA and TO-901317 (Cayman, 
final concentration 10µM/l) to up-regulate ABC transporters.  Cells were washed 
again with PBS and incubated for 4h with medium containing 2% 
apolipoproteinB-depleted serum.  After 4 hours, medium was collected and 
centrifuged at 15,000 rpm for 5min and then aliquots of supernatant were counted in 
liquid scintillation.  The cell layer was washed twice with PBS and incubated with 
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isopropanol for 1h at room temperature, and radioactivity was measured as for the 
supernatant.  Cholesterol efflux was given as the following; the proportion of 
[
3
H]-cholesterol counts in the medium to the total counts present on the well (i.e., 
sum of medium and cells) were calculated, and then background values (i.e., the 
efflux in medium without apolipoproteinB-depleted serum) were subtracted from the 
respective experimental values.  All samples were analyzed in triplicate. 
 
Statistical analysis 
All statistical analyses were performed using Stata10 (College Station, TX, USA).  
All data are expressed as mean ± s.d., unless otherwise specified.  P value for two 
groups was determined by Student’s t-test or the Mann-Whitney test according to the 
data distribution, with or without normality.  The 2-test was used to compare 
categorical variables between the groups.  The differences among multiple groups 
were analyzed by Kruskal-Wallis test.  Multiple regression analyses were performed 
to evaluate the relationship between the prevalence of coronary lesions (ISR, de novo 
lesions, or both) in the CAD group and other clinical parameters. P value <0.05 was 
considered significant.  The receiver operating characteristic curve (ROC curve) 
was used to determine MPO/PON1 ratio cut-off point.  In order to investigate if 
MPO/PON1 ratio provide more effective CAD risk stratification than serum MPO 
levels alone, we calculated net reclassification improvement (NRI) and integrated 
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discrimination improvement (IDI) according to Pencina et al. [13].  The 
associations of MPO and PON1 with other clinical parameters were estimated using 
linear regression analysis.  
 
Results 
Conventional risk markers do not associate with the prevalence of coronary lesions 
in patients with a past history of CAD 
In 158 patients who underwent CAG re-examination, 44 patients showed ISR, 40 
patients had de novo lesions, and 74 patients did not show either ISR or de novo 
lesions.  There were no significant differences in the baseline characteristics, 
including what types of medications they were prescribed, among those groups 
(Table 1).  Original stent types did not vary between the ISR group and the no 
lesion group as shown in Table 1.  The percentage of patients with diabetes mellitus 
seemed higher in the de novo lesion group but no statistical significance was found. 
The LDL-C level of patients with a past history of CAD was lowered to the target 
level (<100 mg/dL) in accordance with the guideline of the Japan Atherosclerosis 
Society for secondary prevention of CAD, while HDL-C levels in the CAD group 
were still lower than those of the non-CAD group (LDL-C, 95.7±23.8 vs. 114.1±31.8, 
p<0.001; HDL-C, 47.2±12.1 vs. 55.6±16.0, p<0.001, respectively).  On the other 
hand, in the CAD group, serum lipid parameters were not related to whether 
restenosis or de novo lesions were present, indicating that quantitative changes in 
lipid profile are not sufficient to predict a recurrence of CAD (Table 2).  Levels of 
hsCRP also had no relationship with the presence or absence of coronary lesions in 
the CAD group. On the other hand, although not statistically significant, HbA1c 
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tended to be larger in the former than in latter (Table 2).  
 
Serum MPO/PON1 ratio is an independent risk indicator of the recurrence of 
coronary artery disease 
We next focused on MPO and PON1 that potentially represent functional qualities of 
plasma lipids and lipoproteins.  First, we compared those markers between patients 
with and without a past history of CAD.  There was no significant difference in 
serum MPO levels between CAD and non-CAD groups (207.1 (158.7-255.5) ng/mL 
vs. 237.8 (202.6-273.0) ng/mL, p=0.324), whereas PON1 activity as paraoxonase 
was significantly lower in the CAD group than in the non-CAD group (220.0 
(209.7-230.3) U/L vs. 251.1 (237.5-264.8) U/L, p<0.001).  Linear regression 
analysis demonstrated weak but significant inverse correlations of PON1 
paraoxonase activity with age (r
2
=0.085) and the rate of concurrent diabetes mellitus 
(r
2
=0.049). Age and the percentage of patients with diabetes mellitus at baseline 
differed significantly between the non-CAD and CAD groups (age, 60.2±13.9 years 
vs. 67.6±10.0 years, P<0.001; diabetes mellitus, 15.7% vs 51.5%, P<0.001, 
respectively), indicating that those factors might affect the decrease in PON1 
paraoxonase activity in CAD patients. 
As shown in Table 2, Kruskal-Wallis test indicated significant differences of serum 
MPO mass and PON1 paraoxonase activity among CAD patients depending on 
whether they had coronary lesion at CAG re-examination.  We also evaluated 
arylesterase activity to elucidate whether PON1 enzyme activity is independent of 
paraoxonase polymorphisms.  Significant differences in arylesterase activity among 
no lesion, de novo lesion, and ISR groups were observed as well (101.0±21.5 U/L vs. 
87.0±15.0 U/L vs. 87.1±16.2 U/L, respectively, P=0.006). 
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When we evaluated the relative effect of these parameters by calculating serum MPO 
mass/PON1 paraoxonase activity (MPO/PON1 ratio), there was no significant 
difference in MPO/PON1 ratio between the non-CAD and CAD groups (1.11 
(0.93-1.30) vs. 1.20 (0.80-1.60), p=0.731).  In contrast, MPO/PON1 ratio was 
significantly different among CAD patients depending on the recurrence of coronary 
lesion (Table 2).  We investigated if co-assessment of PON1 improves the 
diagnostic accuracy of MPO in CAD risk stratification by assessing NRI and IDI.  
The category-free NRI of MPO/PON1 ratio for CAD risk stratification was greater 
than that of MPO alone (39.3% vs 34.7%).  The IDI after addition of MPO/PON1 
ratio to the established risk factors (gender, age, smoking, hypertension, diabetes 
mellitus and dyslipidemia) was also large compared with that of MPO alone (10.4% 
vs. 8.8%).  In multivariate logistic regression analysis that adjusted for age, gender, 
history of smoking, hypertension, dyslipidemia, and diabetes mellitus, elevated 
MPO/PON1 ratio was associated with the prevalence of coronary lesion (ISR or de 
novo lesion) in the CAD group (OD 1.11, 95% CI 1.36-6.12, P=0.006).  The 
prognostic cutoff for MPO/PON1 ratio was set according to the ROC curve at 1.59 
(see supplementary appendix), with sensitivity, specificity, and overall accuracy of 
25.4%, 98.6%, and 64.4%, respectively.  The area under the curve was 0.662 (95% 
CI 0.570-0.753). Logistic regression analysis, adjusted for the factors indicated 
above, revealed that MPO/PON1 ratio >1.59 was independently associated with 
incidence of both ISR and de novo lesion as shown in Table 3. 
 
MPO/PON1 ratio represents anti-inflammatory function and Cholesterol efflux 
capacity of HDL 
Meanwhile, we also investigated whether serum MPO/PON1 ratio is associated with 
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the HDL properties using ex vivo systems.  First, a relationship between 
MPO/PON1 ratio and anti-inflammatory function of HDL was examined.  
Complementary cell culture experiments revealed that TNF markedly increased 
VCAM-1 expression in HUVEC, and the cytokine-induced VCAM-1 expression was 
significantly attenuated by pretreatment of the cell with HDL from CAD patients 
(Figure 2A).  Interestingly, the inhibitory effect of HDL was greater with low 
MPO/PON1 ratio than that with high MPO/PON1 ratio (Figure 1A).  Such 
relationships were held among non-CAD patients (Figure 1B). 
Next, to assess the impact of MPO/PON1 ratio on cholesterol efflux from 
macrophage, ex vivo efflux experiments were performed.  Cholesterol efflux 
capacity of apolipoprotein B-depleted serum was reduced by approximately 6.3 % in 
patients with MPO/PON1 ratio >3 compared patients with MPO/PON1 ratio <1 
(MPO/PON1 <1 group vs. MPO/PON1 >3 group, 25.6±8.4% vs.19.3±5.1%, 
respectively, p<0.05, Figure 2).  
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Discussion 
It has been postulated that MPO acts on LDL and HDL to cause chemical and 
oxidative modifications of the lipid and protein component[6].  In contrast, PON1 
potently protects LDL and HDL from oxidative stress[8].  Thus, it seems reasonable 
that MPO/PON1 ratio represents the function of lipoproteins.  The present study 
demonstrated that MPO/PON1 ratio was independently associated with both 
restenosis and recurrent CAD, while lipid profile and other conventional risk factors 
did not show such relationships.  Moreover, the HDL isolated from patients with 
high MPO/PON1 ratio exhibited attenuated anti-inflammatory properties and 
impairment of cholesterol efflux capacity.  This is the first report that documented a 
direct correlation between MPO/PON1 ratio and function of HDL. 
Two excellent works have previously demonstrated that MPO is a valuable predictor 
for both new-onset CAD and cardiovascular mortality [14, 15].  Both the 
category-free NRI and IDI, novel methods for evaluating improvement in risk 
discrimination[13], of MPO/PON1 ratio for CAD risk stratification was greater than 
that of MPO alone, indicating that combination of PON1 with MPO offers greater 
improvement in CAD risk discrimination than single application of MPO.  
On the other hand, some studies did not document a positive associations between 
MPO and CAD[16].  The reasons for these contradicting results are speculative, but 
assay condition in the measurement would have influenced the outcomes.  Most 
previous studies utilized MPO mass instead of its activity, as is the case with this 
study.  Although strong correlations between MPO mass and activity have been 
reported[16], it remains controversial which reflects the accurate in vivo bioactivity 
of MPO.  Enzymatic activity of MPO depends on local concentration of its 
co-substrate, hydrogen peroxide (H2O2), in vivo[17].  Since MPO activity is 
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measured under saturated amounts of substrate, the ex vivo measurement of serum 
MPO activity may not always reflect the in vivo activity. 
On the other hand, a previous study by Inoue et al. showed that PON1 enzyme 
activities in diabetic patients were significantly lower than those in controls, while 
there were no differences in serum PON1 concentrations between patients and 
controls[18].  Moreover, it has been reported that genetic polymorphism 192Q/R 
affects paraoxonase activity, but not arylesterase activity[18].  Therefore, we 
assessed PON1 activity instead of mass in the present study, and demonstrated that 
both paraoxonase and arylesterase activities were associated with the prevalence of 
coronary lesions in the CAD group, indicating that the results are independent of the 
genetic polymorphism. 
Although the pathogenesis of atherosclerosis and that of restenosis are presumably 
different, the high MPO/PON1 ratio was independently correlated with not only 
occurrence of non-target coronary lesions but also ISR.  Growing evidence indicates 
that oxidative stress plays an important role in the formation of hypertrophic 
neointima through promoting vascular smooth muscle cell proliferation[19].  
Angioplasty induces vascular inflammation[20] and up-regulates NAD(P)H oxidase 
in the vessel wall, followed by superoxide production that can form H2O2[21].  It 
has been shown that MPO is enriched in human atherosclerotic lesions[22].  In the 
presence of H2O2 and chloride, MPO generates the potent oxidant hypochlorous acid 
(HOCl), that can induce endothelial nitric oxide synthase (eNOS) uncoupling, 
whereby eNOS turns into superoxide-producing enzyme[23].  Thus, there is a 
possibility that MPO is involved in the development of restenosis via induction of 
oxidative stress.  On the other hand, Demirbag et al. have recently reported that ISR 
was negatively correlated with paraoxonase and arylesterase activities in patients 
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with bare-metal stents, suggesting that anti-inflammatory and anti-oxidative effects 
of PON1 might contribute to alleviation of restenosis[24].   
Recently, Khera et al. have shown that HDL from CAD patients showed less capacity 
in promoting cholesterol efflux compared to that from health controls and the efflux 
capacity of HDL is a potent determinant of cardiovascular events[25].  Meanwhile, 
Patel et al demonstrated that HDL has less anti-oxidative capacity in patients with 
acute coronary syndrome compared with non-CAD or stable CAD patients[26].  
Thus, accumulating evidence indicates that dysfunctional HDL could be a novel 
therapeutic target for CAD.  However, conventional methods to assess functional 
changes in lipoproteins have not been established for clinical use.  MPO generates 
not only atherogenic LDL but also dysfunctional HDL particles[6].  Recent studies 
demonstrate that MPO modifies apoA-I and reduces its anti-inflammatory and 
anti-oxidative properties[7].  Huang et al. have shown that HOCl produced by MPO 
targets Trp72 of apoA-I and impairs ATP-binding cassette transporter A1-dependent 
cholesterol transport[27].  On the other hand, the decreased PON1 activity is likely 
further to inhibit the anti-atherosclerotic properties of HDL or apoA-I[28].  These 
lines of evidence support our notion that high MPO with low PON1 activity could be 
a substitute marker for dysfunctional HDL. 
In the present study, HDL-C levels in CAD group were lower than in non-CAD 
group.  However, there was no significant difference in MPO/PON1ratio between 
these groups. 
Since this was just a comparison between the presence and absence of past CAD 
history, one plausible explanation is that non-CAD group might have included 
patients with high risk of CAD and vice versa.  On the other hand, MPO/PON1 
ratio was significantly different among CAD patients depending on the prevalence of 
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coronary lesion recurrence, while HDL-C levels did not showed such relationship.  
These findings suggest that quantity of HDL alone is not sufficient for CAD risk 
stratification, and patients with well-preserved HDL property may have less risk for 
CAD than those with dysfunctional HDL, even if their HDL-C levels were low. 
In conclusion, the present findings suggest that serum MPO mass and PON1 activity 
as well as MPO/PON1 ratio could be useful markers for CAD risk stratification 
through modulation of HDL properties. 
 
Study limitations 
There are several limitations in this study.  First, the present study is exploratory 
because the number of participants was small.  In addition, since serum samples 
were obtained when patients underwent CAG re-examination, the present findings 
alone are insufficient to draw a conclusion that MPO/PON1 ratio is a predictor of 
CAD.  Therefore, large prospective randomized studies are further required to 
elucidate the precise role of MPO and PON1 in CAD risk stratification.  Second, we 
measured MPO concentration in serum but not in plasma, while most previous 
studies assessed plasma MPO concentration.  Since PON1 is calcium-dependent, 
and therefore EDTA sensitive, we had to use serum as a sample material.  It should 
be noted that MPO concentrations in serum are generally higher than in plasma 
because clot formation activates granulocytes to release MPO[16].  Third, there is a 
possibility that MPO might promote the progression of atherosclerosis through 
modulation of LDL function.  Recently, Boudjeltia et al. have developed the ELISA 
system to measure circulating levels of LDL modified by the MPO-H2O2-chloride 
system, commonly named Mox-LDL[29].  This sort of method may provide a better 
understanding of this issue.  In addition, serum PON1 activity dose not entirely 
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reflect HDL-associated PON1 activity alone, although it has been reported that 
PON1 exhibited higher activity when it binds with HDL than when it is free, and 
HDL phospholipids affect PON1 catalytic and biological activities[30].  Fourth, it is 
possible that medications might influence serum MPO/PON1 ratio and/or HDL 
property.  In this study, neither of them showed any correlation with patient’s 
medications including statins (data not shown).  However, prospective 
interventional trial is needed to elucidate this issue as well. 
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Figure legends 
Figure 1. Inhibition of tumor necrosis factor (TNF)-α induced vascular cell adhesion 
molecule (VCAM)-1 by high-density lipoprotein (HDL). 
Human umbilical vein endothelial cells were incubated with or without HDL for 16 
hours, and then stimulated with or without 10 ng/ml of TNFα for 6 hours.  HDL 
was purified from patient’s serum with myeloperoxidase/paraoxonase 1 
(MPO/PON1) ratio < 1 or >3.  The expression of VCAM1 and glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) was obtained by real-time polymerase chain 
reaction and the value of VCAM was standardized by GAPDH.  (A) Comparisons 
among CAD patients.  (B) Comparisons among non CAD patients.  P values were 
obtained using analysis of variance and Scheffe’s multiple-comparison t test.  * 
p<0.05 and p<0.01 vs. TNF stimulation without HDL pretreatment. 
 
Figure 2. Effect of MPO/PON1 ratio on HDL efflux capacity. 
THP-1cells were differentiated into macrophages and loaded with [
3
H]-cholesterol 
and TO-901317.  After incubation for 4h with 2% apolipoprotein B-deficient serum, 
cholesterol efflux was measured (n=13 for patients with MPO/PON1<1 and n=15 for 
patients with MPO/PON1>3).  Values represent mean ± S.D.   *Indicates 
statistically significant differences from patients with MPO/PON1<1 (P<0.05) by 
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Student’s t-test. 
 
Supplementary appendix. 
Receiver operating characteristic (ROC) curve for myeloperoxidase/paraoxonase 1 
(MPO/PON1) ratio to identify whether coronary lesions were observed at coronary 
angiography re-examination. 
 
 
